Prices of Daiichi Sankyo Korea’s Lixiana tab. (edoxaban tosylate hydrate), Eisai Korea’s Lenvima cap. (Lenvatinib mesilate), and Janssen Korea’s Trenfya Pre-filled Syringe inj. (guselkumab_genetic recombination) are expected to fall by 2.5% to 4.5% due to their increased usage.

Prices of 10 products including Han Wha Pharma’s Hanwha Topiramate Tablet, Hanwha Donepezil Tablet, and Yooyoung Pharmaceutical’s Cnoxane Injection will also fall by 5.8% to 28.8% at most, following voluntary price cut requests by the companies. Also due to an expansion in the scope of usage, prices of Sanofi-Aventis Korea’s Eloxatin inj., and Lilly Korea’s Alimta inj. will be cut by 1.5% and 2.6% in advance.